Lagerstandorte

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Vorbehaltlich Verfügbarkeit

Dokumentation

MSDS herunterladen

Beispiel-COA herunterladen

Enthält: HPLC, MASS/LC-MS, 1H-NMR, FT-IR, Gehalt, Structure Elucidation Report (SER) sowie zusätzliche analytische Daten je nach Produkt.

176161-56-1Maribavir Impurity 11

● Auf Lager

Katalog-Nr.::	VE0028063
CAS-Nr.::	176161-56-1
Summenformel::	C21H25Cl2N3O7
Molare Masse::	502.35 g/mol

Angebot anfordern

Zur RFQ-Liste hinzufügen

Zusätzliche Informationen zu CAS 176161-56-1

Parent drug

Maribavir

IUPAC-Name

(2S,3S,4S,5S)-2-(Acetoxymethyl)-5-(5,6-dichloro-2-(isopropylamino)-1H-benzo[d]imidazol-1-yl)tetrahydrofuran-3,4-diyl diacetate

Pharmacopeial Synonyms

N/A

Synonyme

N/A

SMILES

ClC1=C(C=C2N(C(NC(C)C)=NC2=C1)[C@@H]3[C@H]([C@H]([C@@H](O3)COC(C)=O)OC(C)=O)OC(C)=O)Cl

InChI

InChI=1S/C21H25Cl2N3O7/c1-9(2)24-21-25-15-6-13(22)14(23)7-16(15)26(21)20-19(32-12(5)29)18(31-11(4)28)17(33-20)8-30-10(3)27/h6-7,9,17-20H,8H2,1-5H3,(H,24,25)/t17-,18-,19-,20-/m0/s1

Beschreibung

Maribavir Impurity 11 (CAS 176161-56-1) is a process- and degradation-related impurity detected in maribavir batches and stability samples, characterized by LC-MS and confirmed by NMR and high resolution mass spectrometry for structural elucidation. It typically coelutes near late-eluting polar degradants in reversed-phase HPLC, requiring tailored chromatographic conditions for robust separation and quantification. Impurity formation is linked to a specific synthetic step and to accelerated storage conditions, making it relevant for control strategy development. Identification, quantitation and qualification per ICH Q3A/Q3B are recommended, with defined acceptance criteria, reference standard preparation and risk assessment for potential toxicological concern.